<SEC-DOCUMENT>0000950103-25-013645.txt : 20251027
<SEC-HEADER>0000950103-25-013645.hdr.sgml : 20251027
<ACCEPTANCE-DATETIME>20251027070506
ACCESSION NUMBER:		0000950103-25-013645
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20251027
FILED AS OF DATE:		20251027
DATE AS OF CHANGE:		20251027

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immatics N.V.
		CENTRAL INDEX KEY:			0001809196
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39363
		FILM NUMBER:		251417436

	BUSINESS ADDRESS:	
		STREET 1:		PAUL EHRLICH-STRASSE 15
		CITY:			TUBINGEN
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 5397 700

	MAIL ADDRESS:	
		STREET 1:		PAUL EHRLICH-STRASSE 15
		CITY:			TUBINGEN
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Immatics B.V.
		DATE OF NAME CHANGE:	20200413
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>dp236283_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>


<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="border-top: Black 3pt solid; font-size: 1pt; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K<BR>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt"><B>REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">October 27, 2025</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->




<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39363</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 22pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMMATICS N.V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Paul-Ehrlich-Stra&szlig;e 15</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>72076 T&uuml;bingen, Federal Republic of Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive office)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form&nbsp;20-F or Form 40-F:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 12pt">Form 20-F</FONT></TD>
    <TD STYLE="width: 14%">
    <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">&#9746;</P></TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 12pt">Form 40-F</FONT></TD>
    <TD STYLE="width: 14%">
    <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">&#9744;&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 3pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-family: Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION CONTAINED IN THIS REPORT ON FORM
6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">On October
27, 2025, Immatics N.V. (the &ldquo;Company&rdquo;) announced the appointment of Amie Krause, as its chief people officer effective October
27, 2025. Ms. Krause&rsquo;s biography is set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="background-color: white">Amie Krause has more
than 20 years of experience in shaping culture, leading organizational growth and aligning talent with business strategy, including across
global biopharmaceutical companies. Prior to joining Immatics, she was Chief Human Resources Officer at Domp&eacute;. Prior to that, she
was Chief People Officer at Revance Therapeutics. She previously served as Chief People Officer at Atara Biotherapeutics, a cell therapy
company. Before Atara, she spent over 10 years at Amgen, where she held multiple senior HR roles, including leading initiatives for global
commercial operations for the Americas, Europe, Asia, Africa and the Middle East. Ms. Krause serves as an Adjunct Professor at California
Lutheran University&rsquo;s School of Management and a guest lecturer at the University of Southern California and the University of Alabama.
Ms. Krause holds both a B.S. in business management and an MBA from California Lutheran University.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">In connection with the foregoing,
the Company issued a press release, a copy of which is attached hereto as Exhibit 99.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INCORPORATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Report on Form 6-K (other than Exhibit 99.1
hereto) shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Nos. 333-249408, 333-265820,
333-280935 and 333-288466) and the registration statements on Form F-3 (Registration Nos. 333-240260, 333-274218 and 333-286151) of Immatics
N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently
filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 85%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><A HREF="dp236283_ex9901.htm"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="font-size: 10pt"><A HREF="dp236283_ex9901.htm"><FONT STYLE="font-size: 10pt">Press release dated October 27, 2025</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-family: Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>IMMATICS N.V.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: October 27, 2025</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Harpreet Singh</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Harpreet Singh</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dp236283_ex9901.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>PRESS RELEASE</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Immatics Appoints Amie Krause as Chief People
Officer</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Houston<FONT STYLE="background-color: white">,
Texas and Tuebingen, Germany, October 27, 2025 </FONT></B><FONT STYLE="background-color: white">&ndash;</FONT> <U STYLE="color: Blue">Immatics N.V.</U> (NASDAQ:
IMTX, &ldquo;Immatics&rdquo; or the &ldquo;Company&rdquo;), a clinical-stage biopharmaceutical company and the global leader in precision
targeting of PRAME, today announced the appointment of Amie Krause as Chief People Officer (&ldquo;CPO&rdquo;) effective October 27,
2025. Ms. Krause brings more than 20 years of experience in shaping culture, leading organizational growth and aligning talent with business
strategy, including across global biopharmaceutical companies. In this newly established role, she will lead Immatics&rsquo; human resources,
focusing on organizational development and operations as the company transitions to commercial stage.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&ldquo;As we enter our next phase of transforming
into a commercial-stage enterprise, we are delighted to welcome Amie. Her experience in building high-performing teams as well as enhancing
organizational excellence and efficiency will help position us for continued success as we strengthen our global leadership in precision
targeting of PRAME,&rdquo; said Harpreet Singh, Ph.D., Chief Executive Officer and Co-Founder of Immatics. &ldquo;Amie is an accomplished
leader in aligning people strategy with business outcomes and will be a critical addition to the leadership team as we advance our pipeline
of PRAME product candidates and prepare for the commercialization of our lead PRAME cell therapy candidate, anzu-cel, with the goal of
providing better options to patients with cancer.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&ldquo;Immatics is at a crucial stage in its journey
to deliver innovative therapies to patients with cancer. I am honored to be joining at such a transformative time and working alongside
a talented team,&rdquo; added Amie Krause, Chief People Officer of Immatics. &ldquo;Building on Immatics&rsquo; strategic vision and diverse
talent, I look forward to fostering a culture that drives organizational excellence and ensures we are ready to deliver on the promise
of our PRAME franchise.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Amie Krause joins Immatics from Domp&eacute;,
where she served as Chief Human Resources Officer. Prior to that, she was Chief People Officer at Revance Therapeutics. She previously
served as Chief People Officer at Atara Biotherapeutics, a cell therapy company. Before Atara, Amie Krause spent over 10 years at Amgen,
where she held multiple senior HR roles, including leading initiatives for global commercial operations for the Americas, Europe, Asia,
Africa and the Middle East. In addition to her industry experience, Amie Krause serves as an Adjunct Professor at California Lutheran
University&rsquo;s School of Management and a guest lecturer at the University of Southern California and the University of Alabama. Amie
holds both a B.S. in business management and an MBA from California Lutheran University.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="font: 11pt Arial, Helvetica, Sans-Serif; width: 78%"><FONT STYLE="font-size: 10pt">Immatics Press Release October 27, 2025</FONT></TD><TD STYLE="text-align: right; width: 22%; font-size: 11pt"><FONT STYLE="font-size: 10pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> | 3</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font-family: Arial, Helvetica, Sans-Serif; margin: 0pt"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>About Immatics</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Immatics is committed to making a meaningful impact
on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers.
Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities,
spanning TCR T-cell therapies and TCR bispecifics.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white">Immatics intends to
use its website <FONT STYLE="color: Blue"><U>www.immatics.com</U></FONT> as a means of disclosing material non-public information. For
regular updates, you can also follow us on <FONT STYLE="color: Blue"><U>LinkedIn</U></FONT> and <U STYLE="color: Blue">Instagram</U>.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white">Certain statements in
this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company&rsquo;s
future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, the timing,
outcome and design of clinical trials, the nature of clinical trials (including whether such clinical trials will be registration-enabling),
the timing of IND, CTA or BLA filings, estimated market opportunities of product candidates, the Company&rsquo;s focus on partnerships
to advance its strategy, and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements
by terminology such as &ldquo;may&rdquo;, &ldquo;should&rdquo;, &ldquo;expect&rdquo;, &ldquo;plan&rdquo;, &ldquo;target&rdquo;, &ldquo;intend&rdquo;,
&ldquo;will&rdquo;, &ldquo;estimate&rdquo;, &ldquo;anticipate&rdquo;, &ldquo;believe&rdquo;, &ldquo;predict&rdquo;, &ldquo;potential&rdquo;
or &ldquo;continue&rdquo;, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements
are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied
by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable
by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible
to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include,
but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties
and factors set forth in the Company&rsquo;s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission
(SEC). Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth
herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place
undue reliance on forward-looking statements, which speak only as of the date they are made. The Company undertakes no duty to update
these forward-looking statements. All the scientific and clinical data presented within this press release are &ndash; by definition prior
to completion of the clinical trial and a clinical study report &ndash; preliminary in nature and subject to further quality checks including
customary source data verification.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="font: 11pt Arial, Helvetica, Sans-Serif; width: 78%"><FONT STYLE="font-size: 10pt">Immatics Press Release October 27, 2025</FONT></TD><TD STYLE="text-align: right; width: 22%; font-size: 11pt"><FONT STYLE="font-size: 10pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> | 3</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font-family: Arial, Helvetica, Sans-Serif; margin: 0pt"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>For more information, please contact:</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><B>Media </B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Trophic Communications</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Phone: +49 151 74416179</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><U STYLE="color: Blue">immatics@trophic.eu</U></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 5.4pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><B>Immatics N.V.</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Jordan Silverstein</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Head of Strategy</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Phone: +1 346 319-3325</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><U STYLE="color: Blue">InvestorRelations@immatics.com</U></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 5.4pt; text-indent: -5.15pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">- END -</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="font: 11pt Arial, Helvetica, Sans-Serif; width: 78%"><FONT STYLE="font-size: 10pt">Immatics Press Release October 27, 2025</FONT></TD><TD STYLE="text-align: right; width: 22%; font-size: 11pt"><FONT STYLE="font-size: 10pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> | 3</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !) ,(# 2(  A$! Q$!_\0
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"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
